The aim of the present work was to investigate the binding properties of the selective AT 1 -receptor antagonist irbesartan to human AT 1 -receptors by direct radioligand binding. For this purpose the specific binding of [ 3 H]-irbesartan to intact Chinese Hamster Ovary (CHO) cells expressing human recombinant AT 1 -receptors was determined. Specific binding of [ 3 H]-irbesartan rapidly reached equilibrium and was saturable with a K D of 1.94 ± 0.12 to a homogeneous class of binding sites. Its binding was inhibited by other AT 1 antagonists (AIIAs) with the same potency order as previous results from [ 3 H]angiotensin II and [ 3 H]-candesartan binding to human AT 1 -receptors. Whereas the dissociation rate of [ 3 H]-irbesartan was essentially independent of the radioligand concentration, it was much slower at 12°C when compared with 37°C. Moreover, the dissociation rate was similar, as determined in washout experiments in the absence or presence of unlabelled AT 1 antagonists. At 37°C the dissociation rate constant corresponded to a half-life of approximately seven minutes, which is sufficient to explain the partially insurmountable inhibition by irbesartan in previous studies. In contrast, other phenomena such as the plasma half life and tissue-related factors are necessary to explain its sustained in vivo antihypertensive effect.
Introduction
It is well documented that the angiotensin II type 1 (AT 1 ) receptor plays a pivotal role in cardiovascular homeostasis and, therefore, there is considerable interest in the therapeutic use of selective antagonists for this receptor in the treatment of hypertension and congestive heart failure. 1 In this respect, irbesartan has been developed as a potent and selective AT 1 -receptor antagonist (AIIA). 2 In vitro studies, in which angiotensin II (Ang II)mediated contraction of isolated rabbit aortic rings/strips is measured, revealed that pre-incubation with irbesartan causes a rightward shift of the concentration-response curve accompanied by an approximately 30% decline of the maximal response. 2 Partially insurmountable inhibition was also found by measuring the Ang II-induced inositol phosphate accumulation in CHO cells expressing the human AT 1 -receptor after pre-incubation with irbesartan. 3 These and other experimental models revealed that the degree by which the maximal Ang II response is depressed by different AIIAs is extremely variable. Whereas there is almost complete reduction of the Ang II responses by GR117289, KRH-594, EXP597 and candesartan and a partial decline by valsartan and EXP3174 (the active metabolite of losartan), no measurable reduction, i.e. surmountable inhibition, is seen with losartan. [3] [4] [5] [6] [7] [8] Several theories have been proposed to explain this particular behaviour of AT 1receptor antagonists. These theories include the presence of allosteric binding sites on the receptor, slowly interconverting receptor conformations, slow removal of the antagonist from tissue compartments, cells or matrix surrounding the receptor, coexistence of different receptor subpopulations, the ability of antagonists to modulate the amount of internalised receptors or two antagonist-induced receptor states with fast and slow dissociation. 9 In this respect, studies in CHO cells expressing human AT 1 -receptors revealed that irbesartan, as well as other insurmountable AT 1 antagonists such as candesartan and EXP3174, inhibit angiotensin II in a mutually exclusive i.e. competitive fashion. 10 Moreover, the insurmountable inhibition by candesartan was found to be related to its slow dissociation from the receptor. When candesartan pretreated cells were washed and exposed to fresh medium, it was demonstrated that functional recovery measuring IP accumulation was slow and coincided with the dissociation of [ 3 H]-candesartan from these cells. 11 As [ 3 H]irbesartan was recently shown to be a suitable radioligand for the specific labelling of AT 1 -receptors in neonatal rat heart cells, we measured the rate of its association and dissociation to CHO-AT 1 cells. 12 Furthermore we investigated whether the dissociation rate was influenced by the radioligand concentration and/or the incubation temperature. Finally, dissociation experiments, under identical conditions as previous functional recovery experiments, were compared using the same assay but with isotopic dilution. The presented results contribute to a more accurate determination and description of the molecular mechanisms behind the partially insurmountable inhibition of Ang II-mediated effects by irbesartan.
Materials and methods

Materials
Candesartan, losartan, EXP3174 and irbesartan were obtained from AstraZeneca (Mölndal, Sweden) and angiotensin II was obtained from Sigma. [ 3 H]-Irbesartan (5 Ci/mmol) was kindly provided by AstraZeneca (Mölndal, Sweden).All other chemicals were of the highest grade commercially available.
Cell culture
Chinese Hamster Ovary cells stably expressing the human angiotensin II AT 1 -receptor (CHO-AT 1 cells) were obtained as described 4 and were cultured in 75 cm 2 flasks in DMEM which was supplemented with L-glutamine (2 mM), 2% of a stock solution containing 5000 IU/ml penicillin and 5000 µg/ml streptomycin (Life Technologies), 1% (v/v) of a solution of MEM containing non-essential amino acids, 1 mM sodium pyruvate and 10% (v/v) fetal bovine serum (Life Technologies). The cells were grown in 12 well plates for [ 3 H]-irbesartan binding.
[ 3 H]-irbesartan binding
Before the experiment, the cells were washed twice with 1 ml per well of DMEM at room temperature. After removal of the medium, 800 µL DMEM was added and the plate was then left for 15 minutes at 37°C. For saturation binding assays, cells were incubated for 30 minutes at 37°C with increasing concentrations of [ 3 H]-irbesartan (final free concentrations ranged between 0.3 and 20 nM) in a volume of 1 ml. For the [ 3 H]-irbesartan dissociation experiments, cells were incubated with 3 or 50 nM radioligand (final volume 1 ml) for 30 minutes at 37°C or for 60 minutes at 12°C. The dissociation of the radioligand was initiated by different procedures: (a) washing of the cells with medium either without or containing 1 µM candesartan (b) addition of 1 µM candesartan or (c) addition of 1 µM unlabelled irbesartan alone or combined with 1 µM candesartan or losartan.The cells were then further incubated for the indicated time periods. In the association rate experiments the cells were incubated for the given time periods.
At the end of each incubation, the cells were 
Results
Specific binding of [ 3 H]-irbesartan to intact adherent CHO-AT 1 cells could be measured in 12 well plates. The binding of 3 nM [ 3 H]-irbesartan was time-dependent and reached equilibrium within 20 minutes at 37°C and within 60 minutes at 12°C ( Figure 1 ). The corresponding pseudo-first-order association rate constants (k obs ) were respectively 0.25 ± 0.05 and 0.042 ± 0.0078 min -1 at 37 and 12°C. Under steady-state conditions, the specific binding of [ 3 H]-irbesartan was saturable (experiments at 37°C; Figure 2 ).The equilibrium dissociation constant (K D ) and B max values calculated by non-linear regression analysis were 1.94 ± 0.12 and 144 ± 18 respectively.The corresponding Hill coefficient was close to unity (n H = 1.02 ± 0.006), indicating a homogeneous population of binding sites in CHO-AT 1 cells. Competition binding experiments with [ 3 H]-irbesartan revealed that all the tested AT 1 -receptor ligands produced a concentration-dependent and complete inhibition of the specific binding ( Figure 3 ). In agreement with the saturation binding experiments, the estimated Hill coefficients were close to unity ( Table 1 ). The potency order of the antagonists (candesartan > EXP3174 > irbesartan ~sar 1 -ile 8 -angiotensin ã ngiotensin II > losartan) was similar to previous binding experiments with [ 3 H]-candesartan and [ 3 H]-angiotensin in the same cells. 3, 11 In contrast, no specific binding of [ 3 H]-irbesartan could be detected on wild type CHO-K1 cells (data not shown). These data indicated that [ 3 H]-irbesartan binds with high specificity to AT 1 -receptors in CHO-AT 1 cells. The dissociation rate of [ 3 H]-irbesartan was monitored under different experimental conditions to investigate the effect of temperature, radioligand concentration and the presence of unlabelled ligands. In the first, so-called 'washout' approach, cells were pre-incubated for 30 minutes with 3 or 50 nM [ 3 H]-irbesartan after which dissociation at 37°C was initiated by washing of the cells with the incubation medium and followed by a further incubation with medium with or without 1 µM unlabelled candesartan. As shown in Table 2 , the dissociation rate was independent of the radioligand concentration, and the k -1 values corresponded to a half-life of approximately seven minutes.The dissociation rate was not affected by The corresponding IC 50 values are given in Table 1 . the presence of candesartan in the washout medium. However, whereas [ 3 H]-irbesartan only dissociated from 85% of the receptors in medium only, dissociation from all the receptor binding sites occurred when 1 µM candesartan was included in the medium.
Antagonist concentration (log M)
The second approach involved the same preincubation with 3 nM [ 3 H]-irbesartan but the dissociation was initiated by addition of a receptor saturating concentration of unlabelled candesartan (1 µM) or irbesartan (1 µM). These experiments were also carried out at 37°C.As outlined in Table 2 , both methods gave k -1 values that were similar to those obtained by the 'washout' method. Furthermore, the dissociation rate by isotopic dilution with 1 µM irbesartan was not changed when combined with 1 µM candesartan or losartan.
Finally, to investigate the effect of the incubation temperature, the cells were pre-incubated with 3 nM [ 3 H]-irbesartan for 30 minutes at 37°C or for 60 min at 12°C and the dissociation rate was measured at the same temperature after addition of 1 µM candesartan. As shown in Figure 4 , the dissociation rate of [ 3 H]-irbesartan was substantially slower at 12°C when compared with 37°C. Combination of the corresponding k -1 values and the pseudo-first-order association rate constants (see above) allowed the calculation of the association rate constants as well as the K D values of [ 3 H]irbesartan at both temperatures. The K D value at 37°C as determined by these kinetic experiments, 2.2 nM, was similar to the one calculated from equilibrium saturation binding experiments. The K D at 12°C, 0.53 nM, was slightly lower.
Discussion
The present study describes the binding properties of the AT 1 antagonist [ 3 H]-irbesartan to CHO cells expressing human AT 1 -receptors. Specific binding of this antagonist occurred solely to the AT 1 -receptors since it was completely displaced by unlabelled AT 1 -receptor antagonists. Their potency order (i.e. candesartan > EXP3174 > irbesartan ~sar 1 -ile 8 -angiotensin ~angiotensin II > losartan) was also identical to the one found for displacing the binding of [ 3 H]-candesartan and of [ 3 H]-angiotensin to cell surface AT 1 -receptors in CHO-AT 1 cells in previous studies. 3, 11 Association of [ 3 H]-irbesartan to the AT 1 -receptors was rapid, reaching an equilibrium within 20 minutes of incubation at 37°C (Figure 1) and, under equilibrium conditions, the receptors behaved as a single class of [ 3 H]-irbesartan binding sites, with an equilibrium dissociation constant of 1.94 nM.
It was previously reported that pre-incubation of CHO-AT 1 cells with irbesartan results in a rightward shift of the Ang II concentration-response curve, along with a partial depression (up to 40%) 
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of the maximal response. 3 Such a partially insurmountable inhibition by irbesartan was also observed when measuring the Ang II-induced contraction of rabbit aorta strips/rings. 2 Several theories, including the presence of allosteric binding sites of the receptor, have been proposed to explain the insurmountable inhibition of AIIAs in general. However, recent evidence from different experimental systems suggests that Ang II and antagonists bind to the AT 1 -receptor in a competitive fashion. 7, [13] [14] [15] [16] This has also been demonstrated by different experimental approaches for the AT 1receptor in CHO-AT 1 cells. First, the non-peptide antagonists candesartan, EXP3174, irbesartan and losartan only produced rightward shifts of the angiotensin II dose-response curve under co-incubation conditions. 13 In the same way, co-incubation with these unlabelled antagonists did not affect the maximal binding of [ 3 H]-candesartan in saturation binding experiments and, finally, addition of EXP3174, irbesartan and losartan did not accelerate the dissociation of [ 3 H]-candesartan in the presence of unlabelled candesartan. 10, 11 Since the dissociation rate of a radioligand is often affected by an allosteric modulation of its binding site, this latter procedure is often adopted for the detection of allosteric ligands. However, in line with the previous findings with [ 3 H]-candesartan, it is shown here that the dissociation rate of [ 3 H]irbesartan remains the same when determined in the presence of unlabelled irbesartan or in the presence of mixtures of irbesartan and of 10 µM losartan or candesartan.This constitutes additional evidence for a competitive type of interaction between AIIAs and, hence, for the binding of these ligands to a syntopic site on the AT 1 -receptor in CHO-AT 1 cells. Because of the competitive nature of surmountable and insurmountable AT 1 -receptor antagonists, it was proposed that the difference in the way they affect the Ang II-mediated response in pre-incubation experiments is related to differ-ences in their dissociation rate from the receptor. 13 When pre-exposed to the receptor, the inhibitory action of insurmountable antagonists may be so slowly reversible that it cannot be overcome during the ensuing short exposure of the receptors to Ang II. On the other hand, the action of surmountable antagonists is readily reversible so that it can be completely overcome upon a subsequent exposure of the receptors to Ang II as suggested in several other studies. [17] [18] [19] [20] [21] Whereas the dissociation of irbesartan from AT 1 -receptors could only be estimated indirectly in previous studies on CHO-AT 1 cells, the availability of tritiated irbesartan now allows direct quantitation. 12 At 37°C, [ 3 H]irbesartan dissociated from AT 1 -receptors in intact CHO-AT 1 cells with a half life of approximately seven minutes. A slower dissociation rate of [ 3 H]irbesartan has been reported for intact rat heart cells (half-life of approximately 50 minutes) but this difference may be related to the fact that those experiments were carried out at room temperature. 12 Indeed, as evidenced by the much slower dissociation of [ 3 H]-irbesartan from its receptors in CHO-AT 1 cells at 12°C (half-life of 110 minutes) as compared with 37°C, it appears that the dissociation rate of this antagonist is highly dependent on temperature.
The half-life of the irbesartan-AT 1 -receptor complex at 37°C exceeds the time during which CHO-AT 1 cells are routinely challenged with Ang II (i.e. five minutes). Hence, when these cells are preincubated with irbesartan, the formed antagonistreceptor complexes will be sufficiently stable to escape complete dissociation during the incubation with Ang II. From the qualitative point of view, there is thus a clear link between the insurmountable effect of irbesartan in functional experiments and the stability of the irbesartan-receptor complex. However, the insurmountable antagonism of irbesartan is only partial and two mechanisms need to be invoked to explain its extent. First, since the half-life of the irbesartan-receptor complex is in the same range as the incubation time with Ang II, partial dissociation will take place during the incubation. The insurmountable effect of irbesartan decreases with time and, in this respect, a marked effect was already noticed for incubation times ranging between one and five minutes. 13 Secondly, in this study it was demonstrated that, even before the incubation with Ang II, only part of the antagonist-AT 1 -receptor complexes reside in a tight binding/insurmountable state (IR*) while the remaining complexes are in a fast reversible/surmountable state (IR). 13 A twostep, two-state receptor model was recently proposed in which the equilibrium between IR and IR* is mainly dictated by k-2i and, hence, by the half-life of IR*. 9 Where I is the antagonist, R the receptor, IR the fast reversible/surmountable antagonist-receptor complex, IR* the tight binding/insurmountable complex and k are kinetic constants.
Data generated by a computer model, which assumes the co-existence of IR and IR* and of the hemi-equilibrium situation during the incubation phase with angiotensin II, closely fitted with the experimental data for irbesartan when the k -2ivalue was set at 0.125 minutes -1 . 9 Since this value closely fits with the observed dissociation rate of [ 3 H]-irbesartan, and since this dissociation behaves as a monomolecular reaction (i.e. linear relationship between ln[binding] and the dissociation time) without a fast initial phase, it is likely that the observed binding of [ 3 H]-irbesartan only involves IR* complexes. IR complexes are likely to be formed in the present radioligand binding studies as well, but their instability may prevent their survival during the wash phase that is necessary to separate free from bound radioligand at the end of each experiment.
The relatively fast dissociation of [ 3 H]-irbesartan from CHO-AT 1 cells in the present study, as well as from intact rat heart cells, does not explain its reported long-lasting blood pressure lowering effect. 22 Indeed, these clinical studies show that daily administration of 150 or 300 mg irbesartan provides 24-hour reduction of blood pressure and that oral administration of 10 mg/kg irbesartan produced approximately 28 hours depression of the Ang II-mediated pressor response in monkeys. 23 Experiments in CHO-AT 1 cells, and comparison of the obtained data with those from contraction studies on intact vascular tissues and from in vivo experiments, could shed light on tissue-or plasma-related phenomena that may contribute to the sustained antihypertensive effect of irbesartan. First, previous dissociation experiments with [ 24 This phenomenon is probably not receptor-related since the [ 3 H]-irbesartan concentration did not affect its dissociation rate in CHO-AT 1 cells. In contrast, it could point at slow removal of the antagonist from compartments within the tissue, cells or matrix surrounding the AT 1 -receptors, as proposed by Panek et al. to explain the long lasting inhibitory effects of certain AT 1 antagonists. 25 Finally, the slow removal of irbesartan from the plasma compartment is likely to constitute a prominent factor. Indeed, pharmacokinetic studies on monkeys revealed a long plasma half life of irbesartan of approximately 20 hours after a single oral dose of 10 mg/kg, along with a correlation between the plasma concentration of irbesartan and its ability to block the hypertensive effect of a bolus injection of angiotensin II. 23 In conclusion, the present in vitro experiments on CHO-AT 1 cells confirm that [ 3 H]-irbesartan is a specific and high affinity radioligand for AT 1 -receptors. Its dissociation rate is highly temperature-dependent but the half-life of seven minutes at 37°C provides an explanation for the only partial insurmountable effect of irbesartan on Ang II concentration-response curves.Yet this relatively fast dissociation of irbesartan from the AT 1receptor does not explain its sustained in vivo antihypertensive effect. The long plasma half-life of irbesartan could therefore be the most prominent contributing factor. Tissue-related factors may have potential importance as well but their contribution still remains to be established.
